Investor Relations

Retrophin, Inc. (NASDAQ:RTRX) is a fully-integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. 

The Company’s strategy centers on advancing its pipeline, in particular its Phase 3 programs for two potential first-in-class therapies: fosmetpantotenate for pantothenate kinase associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood; and sparsentan for focal segmental glomerulosclerosis (FSGS), a serious kidney disorder that often leads to end-stage renal disease. Research exploring additional rare diseases is also underway. Retrophin's R&D efforts are supported by growing revenues from the Company's portfolio of three commercial products.